Sign In
Buy EVOK
$11.00
+0 (+0%)
At Close: Mar 16, 2026
Evoke Resubmits Gimoti™ New Drug Application to FDA
01:30pm, Friday, 20'th Dec 2019
Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA)
Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement
01:30pm, Monday, 02'nd Dec 2019
Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019, it received notification from the Lis
Evoke Pharma Regains Compliance With Nasdaq Minimum Bid Requirement
12:00am, Monday, 02'nd Dec 2019What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shareholder Register?
01:52pm, Monday, 18'th Nov 2019
A look at the shareholders of Evoke Pharma, Inc. (NASDAQ:EVOK) can tell us which group is most powerful. Institutions...
Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price
01:30pm, Wednesday, 13'th Nov 2019
Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 12, 2019, it received notification from the Lis
Evoke Pharma Granted 180-Day Extension By Nasdaq Regarding Minimum Bid Price
12:00am, Wednesday, 13'th Nov 2019Evoke Pharma Reports Third Quarter 2019 Financial Results
01:30pm, Thursday, 07'th Nov 2019
SOLANA BEACH, Calif., Nov. 07, 2019 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.
Evoke Pharma Earlier Reported Q3 EPS $(0.07) Up From $(0.09) YoY
12:00am, Thursday, 07'th Nov 2019Foamix Initiates Phase II Study on Acne Combination Foam
09:14pm, Friday, 20'th Sep 2019
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Come Back To Market?
04:02pm, Thursday, 19'th Sep 2019
Trailing twelve-month data shows us that Evoke Pharma, Inc.'s (NASDAQ:EVOK) earnings loss has accumulated to -US$7.4m...
Zynerba Releases Data on Epilepsy Candidate, Stock Down
02:29pm, Thursday, 19'th Sep 2019
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
